Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data

JOURNAL ARTICLE published November 2017 in Critical Reviews in Oncology/Hematology

Authors: Yaman Tayyar | Luqman Jubair | Sora Fallaha | Nigel A.J. McMillan